BASF Builds New Plant in Germany - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Builds New Plant in Germany


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5
BASF is building a new plant for the production of specialty amines in Ludwigshafen, Germany. The facility, with a total annual capacity of about 12,000 metric tons, is scheduled for completion in 2015. The product range of this multi-product plant comprises 15 amines for different applications. With this new facility, BASF continues to expand its network of amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, Louisiana; and Nanjing, China.

In addition, BASF announced in March that it is building another new multi-product plant for the production of specialty amines at the BASF Verbund site in Nanjing, China. The main products of this plant will be dimethylaminopropylamine (DMAPA) and polyetheramine (PEA). This facility is also expected to be complete in 2015.

Source: BASF

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here